- Home
- MLYS vs HUMA Comparison
MLYS vs HUMA Comparison
Compare MLYS & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- HUMA
- Stock Information
- Founded
- MLYS 2019
- HUMA 2004
- Country
- MLYS United States
- HUMA United States
- Employees
- MLYS N/A
- HUMA N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- MLYS Health Care
- HUMA Health Care
- Exchange
- MLYS Nasdaq
- HUMA Nasdaq
- Market Cap
- MLYS 590.3M
- HUMA 679.3M
- IPO Year
- MLYS 2023
- HUMA N/A
- Fundamental
- Price
- MLYS $13.99
- HUMA $5.59
- Analyst Decision
- MLYS Strong Buy
- HUMA Strong Buy
- Analyst Count
- MLYS 2
- HUMA 8
- Target Price
- MLYS $30.00
- HUMA $11.50
- AVG Volume (30 Days)
- MLYS 152.5K
- HUMA 3.2M
- Earning Date
- MLYS 11-12-2024
- HUMA 11-08-2024
- Dividend Yield
- MLYS N/A
- HUMA N/A
- EPS Growth
- MLYS N/A
- HUMA N/A
- EPS
- MLYS N/A
- HUMA N/A
- Revenue
- MLYS N/A
- HUMA N/A
- Revenue This Year
- MLYS N/A
- HUMA N/A
- Revenue Next Year
- MLYS N/A
- HUMA $4,615.69
- P/E Ratio
- MLYS N/A
- HUMA N/A
- Revenue Growth
- MLYS N/A
- HUMA N/A
- 52 Week Low
- MLYS $5.85
- HUMA $2.08
- 52 Week High
- MLYS $16.91
- HUMA $9.97
- Technical
- Relative Strength Index (RSI)
- MLYS 57.43
- HUMA 47.00
- Support Level
- MLYS $13.33
- HUMA $5.06
- Resistance Level
- MLYS $15.25
- HUMA $5.63
- Average True Range (ATR)
- MLYS 0.63
- HUMA 0.34
- MACD
- MLYS -0.01
- HUMA 0.00
- Stochastic Oscillator
- MLYS 59.25
- HUMA 35.65
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.